Equities Analysts Set Expectations for Sarepta Therapeutics Inc.’s Q3 2016 Earnings (SRPT)
Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Research analysts at SunTrust Banks dropped their Q3 2016 EPS estimates for Sarepta Therapeutics in a research note issued to investors on Tuesday. SunTrust Banks analyst E. Nash now anticipates that the firm will post earnings of ($1.28) per share for the quarter, down from their prior forecast of ($1.12). SunTrust Banks currently has a “Reduce” rating and a $48.00 price target on the stock. SunTrust Banks also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.22) EPS, FY2016 earnings at ($5.20) EPS, FY2017 earnings at ($2.70) EPS, FY2018 earnings at ($1.40) EPS, FY2019 earnings at ($0.42) EPS and FY2020 earnings at $0.52 EPS.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter last year, the company earned ($0.87) earnings per share.
Other analysts have also issued reports about the stock. Piper Jaffray Cos. restated a “sell” rating and issued a $6.00 price objective on shares of Sarepta Therapeutics in a report on Saturday, June 4th. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Wedbush restated a “neutral” rating and issued a $14.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, May 25th. William Blair upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a report on Monday. Finally, Janney Montgomery Scott reiterated a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $51.01.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/equities-analysts-set-expectations-for-sarepta-therapeutics-inc-s-q3-2016-earnings-srpt.html
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 6.55% during trading on Thursday, reaching $59.90. The company’s stock had a trading volume of 5,206,352 shares. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $60.00. The company’s market capitalization is $2.87 billion. The firm’s 50-day moving average price is $29.05 and its 200-day moving average price is $21.62.
In related news, VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the transaction, the vice president now owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP David T. Howton sold 9,304 shares of the company’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $465,200.00. Following the completion of the transaction, the senior vice president now directly owns 11,168 shares of the company’s stock, valued at approximately $558,400. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at $154,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at $211,000. First Allied Advisory Services Inc. increased its position in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares in the last quarter. Finally, National Planning Corp increased its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares in the last quarter. 72.09% of the stock is owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.